Breast Cancer
From the Journals
Some adjuvant endocrine therapies better than others for young breast cancer patients
Young women treated for early hormone receptor–positive, HER2-negative breast cancer fare better if their adjuvant endocrine therapy includes...
From the Journals
Low-fat diet reduces risk of death if breast cancer is diagnosed
Death rates were lowered in women assigned to a low-fat diet after breast cancer diagnosis.
Conference Coverage
Quality of life preserved with ribociclib + letrozole for advanced breast cancer
CHICAGO – Health-related quality of life for patients on the combination therapy was equivalent to that of patients on monotherapy in most aspects...
Conference Coverage
SOLE trial: Intermittent letrozole may provide benefit for some breast cancer patients
Temporary treatment breaks are acceptable in some breast cancer patients.
Conference Coverage
ALTTO follow-up: Dual HER2 blockade may benefit HER2+/HR- tumors
CHICAGO – HR– tumors may derive more benefit from dual HER2 blockade.
Conference Coverage
VIDEO: Dr. William J. Gradishar shares breast cancer take-aways from ASCO 2017
Expert provides take-home messages on pertuzumab, PARP inhibitors, and CDK4/6 inhibitors.
Conference Coverage
Short-HER trial: DFS is similar, cardiac toxicity lower with short trastuzumab course
CHICAGO – Nine weeks of treatment with trastuzumab resulted in comparable disease-free and overall survival to that seen with the standard 12...
Conference Coverage
VIDEO: NCI estimation of MBC numbers a start, but more is needed
SEER data on metastatic breast cancer includes only those diagnosed de novo and not women who were diagnosed following a metastatic recurrence of...
Conference Coverage
VIDEO: Metastatic Trial Search links MBC patients to relevant trials
CHICAGO – A breast cancer advocate discusses mixed response from physicians and barriers to trial participation faced by patients.
Conference Coverage
OlympiAD’s positive results spell good news for olaparib in breast cancer
CHICAGO – The OlympiAD trial represents a “major step forward in breast cancer” in terms of both translational medicine and precision medicine.
Conference Coverage
VIDEO: Pertuzumab prolongs disease-free survival in HER2+ early breast cancer
CHICAGO – The risk of an invasive disease-free survival event was reduced 19% when pertuzumab was added to adjuvant chemotherapy and trastuzumab...